Jasper Therapeutics (NASDAQ:JSPR) Trading Down 5% – Should You Sell?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) shares fell 5% during mid-day trading on Monday . The stock traded as low as $0.4551 and last traded at $0.4680. 569,497 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 603,662 shares. The stock had previously closed at $0.4927.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JSPR. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. UBS Group began coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.14.

Jasper Therapeutics Trading Down 5.0%

The firm has a market cap of $13.10 million, a P/E ratio of -0.14 and a beta of 3.01. The business has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.29.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. As a group, equities analysts expect that Jasper Therapeutics, Inc. will post -1.81 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JSPR. Goldman Sachs Group Inc. grew its position in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after acquiring an additional 1,719,602 shares during the last quarter. Acorn Capital Advisors LLC bought a new stake in Jasper Therapeutics during the 3rd quarter worth $3,291,000. Velan Capital Investment Management LP grew its position in Jasper Therapeutics by 86.1% during the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the last quarter. Woodline Partners LP bought a new stake in Jasper Therapeutics during the 3rd quarter worth $2,475,000. Finally, Propel Bio Management LLC bought a new stake in Jasper Therapeutics during the 3rd quarter worth $2,449,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.